Press Releases for MSFT

Press Releases
New Drug Application Submitted For Acurox(r) Tablets
King Pharmaceuticals Provides Update on EMBEDA™ NDA Review
King Completes Acquisition of Alpharma
King Pharmaceuticals Initiates Phase II Clinical Trial Evaluating T-62 as a Treatment for Neuropathic Pain
BenchmarkJournal.Com (Complimentary) Analyst Review for BAX, KG, CVX and WHR
U.S. Federal Trade Commission Provisionally Accepts Consent Decree and Terminates Waiting Period for King Pharmaceuticals’ Acquisition of Alpharma
King Pharmaceuticals Exercises Option to License Fourth Opioid Product From Acura Pharmaceuticals
King Extends Tender Offer for Alpharma
King Pharmaceuticals Announces Submission of New Drug Application for CorVue™
Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
Leading Government and Advocacy Stakeholders Engage in Public Health Dialogue on Improving Disposal of Unused Medications
King Pharmaceuticals To Acquire Alpharma for Approximately $1.6 Billion
Zacks #1 Rank Top Performers: American Science and Engineering, Allegiant Travel, Alpharma, Hanger Orthopedic and Emergency Medical Services
Seven Summits Research Releases Comments on QCOM, HAL, ERTS, KG, and DF
King Pharmaceuticals Reports Third-Quarter 2008 Financial Results
King Pharmaceuticals Announces Date for Release of Third-Quarter 2008 Financial Results
Acura Pharmaceuticals and King Pharmaceuticals Announce Positive Top Line Results of Key Clinical Study Assessing Abuse Liability
King Pharmaceuticals Extends Tender Offer to Acquire Alpharma
Beacon Equity Issues Technical Trade Alerts on Recent Analyst Upgrades: KG, RNOW, ALL, CPO, HRS, VMI
King Pharmaceuticals Responds to Alpharma Inc.
King Commences Cash Tender Offer for Alpharma at $37 Per Share
King to Commence Cash Tender Offer for Alpharma at $37 Per Share
King Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
Pain Therapeutics and King Pharmaceuticals Develop a New Abuse-Resistant Prescription Pain Medication
King Pharmaceuticals Provides Updated Replay Information for Conference Call Regarding Proposed Acquisition of Alpharma
Alpharma Responds to Unsolicited Proposal by King Pharmaceuticals, Inc.
King Proposes Acquisition of Alpharma for $33 Per Share in Cash
Pain Therapeutics and King Pharmaceuticals Announce Final Data of REMOXY Phase III Study at World Pain Congress in Scotland
FDA Accepts REMOXY New Drug Application and Grants Priority Review
FDA Accepts REMOXY New Drug Application and Grants Priority Review
King Pharmaceuticals Reports Second-Quarter 2008 Financial Results
King Pharmaceuticals Supports Time To Talk(TM) Education Campaign
King Pharmaceuticals Announces Date for Release of Second-Quarter 2008 Financial Results and Conference Call
King Pharmaceuticals to Present at Leerink Swann Pain Roundtable Conference
Acurox Tablets Meet Primary Endpoint in Pivotal Phase III Study
Pain Therapeutics and King Pharmaceuticals Announce Submission of New Drug Application for Remoxy
King Pharmaceuticals to Present at Goldman Sachs Global Healthcare Conference
King Pharmaceuticals Reports First-Quarter 2008 Financial Results
King Pharmaceuticals and Acura Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal Phase III Clinical Trial Evaluating ACUROX(TM)
King Pharmaceuticals Announces Date for Release of First Quarter 2008 Earnings